In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ACVC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Role of novel biomarkers of renal injury in patients with st segment elevation myocardial infarction

Session Poster Session 4 - Acute Coronary Syndromes (Other)

Speaker Associate Professor Irina Vishnevskaya

Event : Acute Cardiovascular Care 2018

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes: Biomarkers
  • Session type : Poster Session

Authors : YV Hilova (Kharkiv,UA), IR Vyshnevska (Kharkiv,UA), OV Petyunina (Kharkiv,UA), MP Kopytsya (Kharkiv,UA)

YV Hilova1 , IR Vyshnevska1 , OV Petyunina1 , MP Kopytsya1 , 1Government institution“L.T. Malaya Therapy National institute of the National academy of medical sci - Kharkiv - Ukraine ,

European Heart Journal Supplement ( 2018 ) 7 ( Supplement ), S267

Worsening renal function (WRF) significantly associated with the adverse prognosis of patients with acute coronary syndrome (ACS). ST-2 is a novel and promising biomarker in the evaluation prognosis for ACS patients. sST2 as an emerging marker of reduced kidney function in ACS patients is being actively studied.
Purpose: to determine prognostic significance of sST2 and other biomarkers in prognosis of patients with reduced renal function and ACS.
Methods: 103 patients were screened with ST segment elevation myocardial infarction (STEMI) (75 male and 28 female), mean age was 61,85 ± 12,23 years. All patients had to undergo baseline investigations, including the level of serum creatinine; the glomerular filtration rate (GFR) was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. Accordingly to the result, all patients have been divided into two groups with the GFR level less (the 1st group) and greater (the 2nd group) than 60 mL/min/1.73 m2. In addition, during the first day of hospitalization the sST2 and N-terminal pro-brain natriuretic peptide (NT-pro BNP) were determined.
Results: we calculated the GFR, the average was 70,40±26,29 mL/min/1.73 m2. In the 1st group of patients the average GFR was 45±1,32 ml/min/1.73m2, in the 2nd - 73±2 ml/min/1.73m2. There was significant difference between level of GFR in those group of patients (p < 0,0001). During the statistical analysis the mean value of sST2 in the first group was 84,06 pg/ml, in the second – 52,84 pg/ml; the mean value for NT- pro BNP was 846.69 pg/ml and 447,28 pg/ml, respectively. The effect of 60 variables of clinical, instrumental and laboratorial status was assessed on formation of reduced kidney function in patients with different level of GFR. For identification of the main risk factors for WRF, we have used logistic regression (LR): NT-pro BNP (area under curve (AUC) 0.7; p < 0.05; 95% confidence interval (CI): 0.52 – 0.8; sensitivity (Se) 63%, specificity (Spe) 71%), sST2 (AUC 0.63; p < 0.02; 95% CI: 0.52 – 0.74; Se 83%, Spe 41%) were main risk factors for WRF predicting.
Conclusions: The biomarker sST2 can be used for risk stratification in WRF in patients with STEMI; it’s as sensitive as the known marker NT- pro BNP. For high prognostic possibility we can use combination of biomarkers.

The free consultation period for this content is over.

It is now only available year-round to ACVC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are